◆ EGFR◆ KRAS◆ TP53◆ BRCA1◆ HER2◆ VEGFR◆ CDK4/6◆ PD-L1◆ PARP◆ BCR-ABL◆ mTOR◆ ALK◆ BRAF◆ RET◆ MET◆ EGFR◆ KRAS◆ TP53◆ BRCA1◆ HER2◆ VEGFR◆ CDK4/6◆ PD-L1◆ PARP◆ BCR-ABL◆ mTOR◆ ALK◆ BRAF◆ RET◆ MET
AI-Native Drug Repurposing
The cure
was already
there.
Metformin sat in medicine cabinets for 50 years before anyone tried it on cancer. Helix surfaces those discoveries in minutes — not decades.
~$1B
Cost of new drug development
10–15yr
Traditional approval timeline
<4min
Helix analysis time
9,000+
FDA-approved drugs to mine
— The Pipeline
One input.
Full research
pipeline.
01
Literature Synthesis
AI agents crawl arXiv and deep research databases to build a current knowledge base for your target cancer type.
02
Target Identification
High-impact proteins like EGFR, KRAS, and p53 are extracted with known mechanisms and FDA status.
03
Structure Retrieval
High-resolution protein structures fetched from RCSB. Compounds sourced from PubChem and canonicalized.
04
GPU Docking Simulation
DiffDock runs on Nvidia Blackwell GPUs — physics-informed diffusion modeling ranks binding confidence across all candidates.
05
Ranked Report
Repurposing candidates surface with confidence scores, mechanisms, and a shareable research report.
Helix © 2025AI-native drug repurposing